GSK Looks Toward Regulatory Filing for Once-Weekly Diabetes Drug

GSK is readying for regulatory filings for its once-weekly injectable Type 2 diabetes treatment albiglutide after positive Phase III results in its second completed trial and primary endpoint data from five ongoing studies. Albiglutide, a glucagon-like peptide-1 (GLP-1) agonist, is being investigated as both a monotherapy and add-on therapy. It boasted encouraging results in its second completed Phase III study, Harmony 6, achieving noninferiority to preprandial insulin.
Washington Drug Letter